Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document
Yolande Lievens(Ghent University Hospital), Wendy A. Woodward(The University of Texas MD Anderson Cancer Center), Puneeth Iyengar(Memorial Sloan Kettering Cancer Center), I. Kindts(AZ Groeninge), Daniel R. Gomez(Cedars-Sinai Medical Center), Umberto Ricardi(Azienda Ospedaliero Universitaria San Giovanni Battista), James B. Yu(Harvard University), Marta Scorsetti(Humanitas University), Alejandra Romero(Erasmus MC), David A. Palma(Western University), Morten Høyer(Aarhus University Hospital), Daan Nevens(University of Antwerp), Catherine Park(UCSF Helen Diller Family Comprehensive Cancer Center), Matthias Gückenberger(University Hospital of Zurich)
Cited by 646
Related Papers
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
|The Lancet|2019|1.9k
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study
|Journal of Clinical Oncology|2019|1.3k
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
|Journal of Clinical Oncology|2020|1.2k